Abstract
Protein kinase CK2 (Casein Kinase 2) is an essential, ubiquitous and highly pleiotropic protein kinase, implicated in several human diseases. In the last decade, several inhibitors of CK2, have been discovered and characterized to be ATP-competitive compounds. However, only one of them, CX-4945, has recently completed Phase I clinical trial as potential anticancer drug. In this review, we report all chemical classes of CK2 inhibitors available in literature, focusing our attention on conventional ATP-competitive and on non ATP-competitive inhibitors, which could represent a new frontier in CK2 inhibition and, consequently, a promising field of study in discovering new drug candidates.
Keywords: CK2, protein kinases, enzymes, kinase inhibitors, multi kinase inhibitors, cell cycle, cell signaling, apoptosis, cancer, neurodegenerative diseases, infections.
Current Medicinal Chemistry
Title:Kinase CK2 Inhibition: An Update
Volume: 20 Issue: 5
Author(s): G. Cozza, L. A. Pinna and S. Moro
Affiliation:
Keywords: CK2, protein kinases, enzymes, kinase inhibitors, multi kinase inhibitors, cell cycle, cell signaling, apoptosis, cancer, neurodegenerative diseases, infections.
Abstract: Protein kinase CK2 (Casein Kinase 2) is an essential, ubiquitous and highly pleiotropic protein kinase, implicated in several human diseases. In the last decade, several inhibitors of CK2, have been discovered and characterized to be ATP-competitive compounds. However, only one of them, CX-4945, has recently completed Phase I clinical trial as potential anticancer drug. In this review, we report all chemical classes of CK2 inhibitors available in literature, focusing our attention on conventional ATP-competitive and on non ATP-competitive inhibitors, which could represent a new frontier in CK2 inhibition and, consequently, a promising field of study in discovering new drug candidates.
Export Options
About this article
Cite this article as:
Cozza G., Pinna A. L. and Moro S., Kinase CK2 Inhibition: An Update, Current Medicinal Chemistry 2013; 20 (5) . https://dx.doi.org/10.2174/092986713804999312
DOI https://dx.doi.org/10.2174/092986713804999312 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imiquimod
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry High Throughput Screening of Normal and Neoplastic Tissue Samples
Combinatorial Chemistry & High Throughput Screening A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Reducing radiation in chronic total occlusion percutaneous coronary interventions
Current Cardiology Reviews The Cross-talk between Tristetraprolin and Cytokines in Cancer
Anti-Cancer Agents in Medicinal Chemistry Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy CIAPIN1 siRNA Inhibits Proliferation, Migration and Promotes Apoptosis of VSMCs by Regulating Bcl-2 and Bax
Current Neurovascular Research Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Tumorspheres Derived from HCC Cells are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases
Current Protein & Peptide Science MicroRNAs in Human Diseases
Recent Patents on DNA & Gene Sequences Full Length and Delta Lactoferrin Display Differential Cell Localization Dynamics, but do not Act as Tumor Markers or Significantly Affect the Expression of Other Genes
Medicinal Chemistry Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies
Current Pharmaceutical Design Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials Respiratory Stem Cells and Progenitors: Overview, Derivation, Differentiation, Carcinogenesis, Regeneration and Therapeutic Application
Current Stem Cell Research & Therapy